Genta’s SPA OK, But Firm Waits For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency agrees to special protocol assessment, but Genta will not start trial of Genasense in previously untreated patients until discussions are held on pending application for relapsed/refractory patients.